SILK ROAD MEDICAL INC (SILK)

Company Profile

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. The company is headquartered in Sunnyvale, California and currently employs 414 full-time employees. The company went IPO on 2019-04-04. The firm has discovered an approach for the treatment of carotid artery disease called transcarotid artery revascularization, (TCAR), which relies on two concepts: minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain and combines the endovascular techniques with fundamental surgical principles. Its product portfolio includes ENROUTE Transcarotid Neuroprotection System (NPS), ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014 Guidewire, and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. Its ENROUTE Transcarotid Stent System is placed during a period of temporary high-rate blood flow reversal, which is enabled by its ENROUTE Transcarotid NPS. The company markets and sells products in the United States through a direct sales organization.

Company Info

SILK ROAD MEDICAL INC

1213 Innsbruck Dr

Sunnyvale CALIFORNIA 94089

P: 16505669060

CEO: Erica J. Rogers

Employees: 414

Website: https://silkroadmed.com/